Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Short-term Investments: 2016-2025

Historic Short-term Investments for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Sep 2025 value amounting to $364.0 million.

  • Rhythm Pharmaceuticals' Short-term Investments rose 45.09% to $364.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $364.0 million, marking a year-over-year increase of 45.09%. This contributed to the annual value of $231.4 million for FY2024, which is 7.26% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Short-term Investments stood at $364.0 million for Q3 2025, which was up 134.15% from $155.4 million recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Short-term Investments ranged from a high of $364.0 million in Q3 2025 and a low of $122.4 million during Q2 2022.
  • Its 3-year average for Short-term Investments is $208.1 million, with a median of $208.4 million in 2025.
  • Per our database at Business Quant, Rhythm Pharmaceuticals' Short-term Investments slumped by 59.04% in 2022 and then skyrocketed by 45.09% in 2025.
  • Over the past 5 years, Rhythm Pharmaceuticals' Short-term Investments (Quarterly) stood at $235.6 million in 2021, then fell by 12.73% to $205.6 million in 2022, then climbed by 4.94% to $215.8 million in 2023, then rose by 7.26% to $231.4 million in 2024, then spiked by 45.09% to $364.0 million in 2025.
  • Its Short-term Investments was $364.0 million in Q3 2025, compared to $155.4 million in Q2 2025 and $208.4 million in Q1 2025.